Cardiovascular therapeutics form a central part of the global pharmaceutical market, with a wide range of treatments, including leading blockbusters. As the patient population grows and cardiovascular diseases become more prevalent, cardiovascular drugs have the potential for continued sales growth in both mature and emerging markets.
Our new pharma report - Global Cardiovascular Drugs Market 2009-2024 - explains how, showing you where the opportunities for growth will lie from 2009 onwards.
Predictions state that total revenues in the cardiovascular disorders market will increase steadily from 2009. This report reviews commercial prospects for therapeutics directly related to cardiovascular incidents, agents such as platelet aggregation inhibitors, anticoagulants and fibrinolytics in particular. We include preventive therapeutics - such as antihypertensives and statins - in the overall analysis, even although they are not the main focus of this report.
The years 2011 to 2015 will mark a period of high volatility in the cardiovascular market as key products - including blockbusters Plavix and Lovenox - face patent expiry. What types of therapeutic agent will enter the market from 2009 onwards, and what are their sales prospects? Where do the main opportunities lie, and what are the threats in this market? What are the principal market drivers and restraints?
This report will provide you with the analytical information that you need to understand current trends and future prospects in this market area, covering those and other questions.
In particular, we discuss commercial prospects for the following products in detail, including future sales values:
- Platelet aggregation inhibitors
- Anticoagulant drugs
- Nitrates
- Fibrinolytics.
Comprehensive analysis of the cardiovascular market area
Global Cardiovascular Drugs Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are 60 tables and figures and three full interviews with experts. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.
Why you should buy Global Cardiovascular Drugs Market 2009-2024
Through buying this report you will receive the following benefits:
- You will receive a review of the existing market for cardiovascular disorder therapeutics
- You will receive overall revenue forecasts from 2009 to 2024, at whole market and sub-market levels for the sector
- You will find out where leading products and companies are heading, with detailed sales forecasts from 2009 to 2024
- You will receive forecast revenues for leading geographical markets
- You will receive expert opinions from original research interviews
- You will receive well-informed analyses of market drivers and restraints, including SWOT analysis for the cardiovascular sector
- You will receive important pipeline information, seeing how present R&D is shaping the future of the cardiovascular market.
1 Executive Summary
1.1 Aims of This Report
1.2 Chapter Overview
2 Cardiovascular Disease: An Overview
2.1 Financial Cost
2.2 Types of Cardiovascular and Cerebrovascular Disease
2.2.1 Ischaemic Heart Disease
2.2.2 Stroke
2.2.3 Acute Myocardial Infarction
2.2.4 Other Disorders
2.3 Risk Factors
2.4 Prevalence
2.4.1 Ischaemic Heart Disease Remains the World’s Leading Cause of Death
2.4.2 Hypertensive Heart Disease on the Rise
3 Therapeutic Categories
3.1 Platelet Aggregation Inhibitors
3.1.1 Glycoprotein Inhibitors
3.1.2 COX Inhibitors and Aspirin
3.1.3 Thienopyridines
3.2 Anticoagulants
3.2.1 Heparins
3.2.2 Vitamin K Antagonists and Warfarin
3.2.3 Combined Therapy
3.3 Nitrates
3.4 Thromobolytics and Fibrinolytics
3.4.1 Streptokinase and Urokinase
3.4.2 Tissue Plasminogen Activators (t-PA)
3.4.3 Other Thrombolytic Agents
3.5 Cardiac Glycosides
3.6 Anti-Arrhythmic Agents
3.7 Prevention of Disease
3.7.1 Antihypertensives
3.7.2 Lipid-Lowering Treatments
4 Global Market 2009-2024
4.1 Key Findings
4.2 Leading Companies
4.3 Forecast for the Overall Cardiovascular Market, 2009-2024
4.4 The Market for Acute Cardiovascular Therapeutics, 2009-2024
4.5 The Future of Blockbusters in the Market
4.6 Overview of the Market
5 Platelet Aggregation Inhibitors, 2009-2024
5.1 Key Findings
5.2 Platelet Aggregation Inhibitors Market, 2009-2024
5.3 High Revenues
5.4 Top Product Plavix
5.4.1 Generic Competition Set to Strike
5.4.2 Branded Competition: Marketed and in the Pipeline
5.5 Otsuka Pharmaceutical’s Pletal
5.5.1 Pletal Facing Several Abbreviated New Drug Applications
5.6 Boehringer Ingelheim’s Asanantin
5.6.1 Aiming for Higher Revenues
5.7 Aspirin Cardio
5.7.1 OTC Treatments for the Prevention of Cardiovascular Disease?
5.8 The Future of Platelet Aggregation Inhibitors
6 Anticoagulants, 2009-2024
6.1 Key Findings
6.2 Total Anticoagulant Market, 2009-2024
6.3 Heparins Market, 2009-2024
6.4 Lovenox Leads the Market
6.4.1 Competition for Lovenox
6.5 Fragmin
6.5.1 Life Cycle Management and Competition
6.6 Fraxiparine
6.7 Market Share for Heparins, 2009, 2014, 2019 and 2024
6.8 Vitamin K Antagonists Market, 2009-2024
6.8.1 Leading Product Coumadin
6.8.2 Generic Competition for Warfarin
7 Nitrates, 2009-2024
7.1 Key Findings
7.2 Nitrates Market, 2009-2024
7.3 The Future of Nitrates
8 Fibrinolytics, 2009-2024
8.1 Key Findings
8.2 Fibrinolytics, 2009-2024
8.3 Activase: Leading the Category
8.3.1 Competition and the Treatment Window
8.4 Second-Generation Drug Metalyse: Aiming for the Top?
8.4.1 Mode of Administration May Give Metalyse the Edge
8.4.2 ASSENT and TROICA Studies: A Mixed Message
9 Other Product Categories, 2009-2024
9.1 Cerebral and Peripheral Therapeutics
9.1.1 New Products in the Pipeline
9.2 The Future of Anti-Arrhythmic Agents
9.2.1 Thin Pipeline and Safety Scares
9.3 Cardiac Glycosides: Low Revenues
9.3.1 Digitalis: Alleviating Symptoms or Ineffective Therapy?
10 Preventive Therapeutics, 2009-2024
10.1 Key Findings
10.2 Antihypertensives
10.2.1 Forecast for the Overall Antihypertensive Market, 2009-2024
10.2.2 Angiotensin II Antagonists Lead the Market
10.2.3 Generic Threat
10.2.4 Overall Assessment of the Market
10.3 Lipid-Lowering Therapeutics, 2009-2024
10.3.1 Forecast for the Overall Lipid Lowering Market, 2009-2024
10.3.2 Statins: A Success Story So Far
10.4 High Revenues
11 Geographical Breakdown of the Market
11.1 USA
11.2 Europe
11.3 Emerging Markets
11.3.1 China
11.3.2 India
12 SWOT Analysis of the Market
12.1 Principal Drivers
12.1.1 Increasing Prevalence of Disease Drives the Market
12.1.2 High Economic Cost of Disease
12.1.3 Risk Factors: Management Rather than Cure
12.1.4 Switching to OTC
12.1.5 Novel Therapeutics Poised to Meet Needs in the Patient Population
12.2 Principal Restraints
12.2.1 The Threat of Generic Products
12.2.2 Downward Cost Pressures
12.2.3 Buyer’s Market?
12.2.4 Maturation of the Overall Market May Limit Growth
12.2.5 Antihypertensives: Is the Market Maturing?
12.2.6 Challenges to the Statins Industry
12.3 Concluding Remarks on the Future of the Market
13 Expert Opinions
13.1 Professor Jeremy Pearson
13.1.1 The Future of Stem Cells in the Treatment of Cardiovascular Disorders
13.1.2 Time Frame for Research and Development
13.1.3 Current Challenges for This Type of Therapeutics
13.2 Dr Mariola Söhngen
13.2.1 Unmet Needs for Patients Suffering from Ischaemic Strokes
13.2.2 Trends in Research and Development
13.2.3 Limitations of Anti-Clotting Drugs: New Developments
13.3 Dr Josh Reece
13.3.1 The Future of Stem Cells in the Treatment of Cardiovascular Disorders
13.3.2 Stem Cells: Niche or Mainstream?
13.3.3 Osiris Therapeutics’ Prochymal
14 Pipelines and Future Trends
14.1 Gene Therapy: A Growing Area of Research
14.1.1 Potential Therapeutic Areas
14.1.2 Public Acceptance of Gene Therapy
14.2 Stem Cells: High Potential?
14.2.1 Osiris Therapeutics
14.2.2 ReNeuron
14.3 Treatment Windows and New Opportunities
14.4 Novel Antithrombotic Drugs: Limitations in the Existing Market
14.4.1 Servier’s Terutroban
14.4.2 AstraZeneca’s Brilinta
14.4.3 Schering-Plough’s Protara
14.4.4 Schering-Plough’s SCH 530348
14.5 Long-Term Oral Anticoagulants
15 Conclusions
15.1 High Revenues
15.2 Impending Patent Expiries
15.3 Expanding Market
15.4 Rehabilitation on the Rise
15.5 Summary
List of Tables
Table 2.1 Leading Causes of Death World Wide, 2004 and 2030
Table 3.1 Antihypertensive Drugs, Their Effects and Side Effects
Table 3.2 Factors Influencing Plasma Lipid Levels
Table 4.1 Leading Companies in the Cardiovascular Therapeutic Market, World Sales ($m) and Market Share (%), 2008
Table 4.2 Cardiovascular Market, World Sales ($m), 2009-2024
Table 4.3 Acute Therapeutics by Category, World Sales ($m) and Market Share (%), 2009 and 2014
Table 4.4 Key Products in the Cardiovascular Market, World Sales ($m) and Market Share (%), 2008
Table 5.1 Platelet Aggregation Inhibitors, World Sales ($m), 2008-2014
Table 5.2 Platelet Aggregation Inhibitors, World Sales ($m), 2009, 2014, 2019 and 2024
Table 6.1 Anticoagulants, World Sales ($m), 2008-2014
Table 6.2 Anticoagulants, World Sales ($m), 2009, 2014, 2019 and 2024
Table 6.3 Heparins, World Sales ($m), 2008-2014
Table 6.4 Heparins, World Sales ($m), 2009, 2014, 2019 and 2024
Table 6.5 Vitamin K Antagonists, World Sales ($m), 2009, 2014, 2019 and 2024
Table 7.1 Nitrates, World Sales ($m), 2008-2014
Table 7.2 Nitrates, World Sales ($m), 2009, 2014, 2019 and 2024
Table 8.1 Fibrinolytics, World Sales ($m), 2008-2014
Table 8.2 Fibrinolytics, World Sales ($m), 2009, 2014, 2019 and 2024
Table 9.1 Other Product Categories, World Sales ($m), 2008-2014
Table 9.2 Other Product Categories, World Sales ($m), 2009, 2014, 2019 and 2024
Table 10.1 Antihypertensive Market, World Sales ($m), 2008-2014
Table 10.2 Lipid-Lowering Therapeutics, World Sales ($m), 2008-2014
Table 10.3 Lipid-Lowering Therapeutics, World Sales ($m), 2009, 2014, 2019 and 2024
Table 11.1 Geographical Breakdown of the World Market, World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 12.1 SWOT Analysis for the Cardiovascular Market, 2009
List of Figures
Figure 4.1 Leading Companies in the Cardiovascular Therapeutic Market, Market Share (%), 2008
Figure 4.2 Preventive vs. Acute Therapeutics, Market Share (%), 2009, 2014, 2019 and 2024
Figure 4.3 Sales ($m) for the Global Cardiovascular Market, 2008-2024
Figure 4.4 Acute Therapeutics by Category, Market Share (%), 2008
Figure 4.5 Sales ($m) for the Global Acute Cardiovascular Therapy Market, 2008-2024
Figure 5.1 Market Share (%) for the Leading Products in the Platelet Aggregation Inhibitor Market, 2008
Figure 5.2 Plavix, World Sales ($m), 2008-2024
Figure 5.3 Pletal, World Sales ($m), 2008-2024
Figure 5.4 Asanantin, World Sales ($m), 2009-2024
Figure 5.5 Aspirin Bayer, World Sales ($m), 2008-2024
Figure 5.6 Platelet Aggregation Inhibitors, Key Products Market Share (%), 2009, 2014, 2019 and 2024
Figure 6.1 Anticoagulants, World Sales ($m), 2008-2024
Figure 6.2 Heparins, World Sales ($m), 2008-2024
Figure 6.3 Anticoagulants, Market Share (%), 2008
Figure 6.4 Lovenox, World Sales ($m), 2008-2024
Figure 6.5 Fragmin and Fraxiparine, World Sales ($m), 2008-2024
Figure 6.6 Heparins, Market Share (%), 2009, 2014, 2019 and 2024
Figure 6.7 Vitamin K Antagonists, World Sales ($m), 2009-2024
Figure 6.8 Vitamin K Antagonists, Market Share (%), 2008
Figure 6.9 Vitamin K Inhibitors, Market Share (%), 2009, 2014, 2019 and 2024
Figure 7.1 Nitrates, World Sales ($m), 2008-2024
Figure 8.1 Activase, World Sales ($m), 2008-2024
Figure 8.2 Metalyse, World Sales ($m), 2008-2024
Figure 8.3 Key Fibrinolytics, Market Share (%), 2009, 2014, 2019 and 2024
Figure 9.1 Other Product Categories, World Sales ($m), 2009, 2014, 2019 and 2024
Figure 10.1 Antihypertensives, World Sales ($m), 2008-2024
Figure 10.2 Market Share (%) for the Various Types of Antihypertensives, 2008
Figure 10.3 World Sales ($m) for Statins and Non-Statin Lipid-Lowering Therapeutics, 2008-2024
Figure 10.4 Market Share (%) for Cholesterol Lowering Therapeutics, 2008
Figure 10.5 Types of Statins, World Sales ($m), 2008
Figure 10.6 Preventive and Acute Therapeutics, Market Share (%), 2008
Figure 11.1 Geographical Breakdown of the World Market, Market Share (%), 2008
Figure 11.2 Market Share (%) for Key Countries, 2009, 2014, 2019 and 2024
Figure 11.3 Market Share (%) for the European Market, 2009, 2014, 2019 and 2024
Figure 11.4 Geographical Areas Market Share (%), 2009, 2014, 2019 and 2024
Acino
Almirall
Alpharma
Amphastar Pharmaceuticals
AnGes MG
Apotex
AstraZeneca
Barr
Bayer Schering Pharma
Biovail Pharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb
Centocor
Chiesi Pharmaceuticals
Choong-Wae Pharmaceuticals
Chorepharma
Daiichi Sankyo
Dainippon Sumitomo
Dong-A
Eli Lilly
Eon Labs
Esteve
Genentech
Genzyme
GlaxoSmithKline
Ipsen
Johnson & Johnson
Kyowa Hakko
LIBBS
Meda
Menarini
Merck & Co
Mitsubishi Kasei
Mitsubishi Tanabe
Momenta Pharmaceuticals
Mylan
Novartis
Nycomed
Otsuka
Paion
Pfizer
Portola
Ranbaxy
Ratiopharm
ReNeuron
Roche
Sandoz
Sanofi-Aventis
Servier
Sigma-Tau
Shionogi
Solvay
Taro (Israel)
Teva Pharmaceutical Industries
Watson
Other selected research from the 'Drugs' category:
Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2012
Other selected research from the 'Cardiovascular' category:
Cardiac Rhythm Management Devices World Markets
Global Cardiovascular Drugs Market 2009-2024